• Clinical Trial

    Allist will strive to take its advantages in new drug discovery, increase R&D inputs, and intensify its efforts in accelerating exploring targeted drugs for cancer treatment.Meanwhile, Allist is working to expand its product pipeline in multiple ways including joint development and external introduction.

    Furmonertinib
    (Core product)

    • Approved
    Second-line therapy for Non-small Cell Lung Cancer (NSCLC):EGFR T790M mutation-positive, locally advanced or metastatic NSCLC
    • PHASE III CLINICAL TRIAL
    First-line therapy for Non-small Cell Lung Cancer (NSCLC):EGFR mutation-positive, locally advanced or metastatic NSCLC
    • Phase III enrollment
    Postoperative adjuvant therapy of NSCLC:Postoperative adjuvant therapy for patients with EGFR mutation-positive NSCLC at phase 1I-IIIa
    • Phase Ib enrollment
    Second-line therapy for NSCLC:Applicable to advanced NSCLC with EGFR ex20ins mutation
    • Phase Ib enrollment
    First-line therapy for NSCLC:Applicable to advanced NSCLC with EGFR ex20ins mutation

    RETinhibitor

    • Preclinical study
    NSCLC

    KRAS G12C
    inhibitor

    • Preclinical study
    NSCLC, colorectal cancer, pancreatic cancer

    KRAS G12D
    inhibitor

    • Preclinical study
    NSCLC, colorectal cancer, pancreatic cancer

    SOS1
    inhibitor

    • Preclinical study
    NSCLC, colorectal cancer, pancreatic cancer

    4th-generationEGFR
    inhibitor

    • Preclinical study
    NSCLC with C797S drug-resistant mutation after treatment with 3rd-generation EGFR inhibitor

    Treatment of Malignant Tumor

    Manufacturing
    • 73,337
      Square meter
    • 240
      Million RMB
      (registered capital)

    As an innovative pharmaceutical industrialization base invested by Shanghai Allist Pharmaceuticals, Jiangsu Allist Pharmaceuticals Co.,LTD was founded in Sept 2009 with a  registered capital of 240 million RMB.Jiangsu Allist is located in No.666 Huashi Road, Qidong Economic Development Zone, Jiangsu Province, covering a total area of 73,337 square meter, 90Km away from Shanghai Pudong Airport, with convenient transportation and beautiful environment.

    Scope of production license: Tablets (including antitumor drugs) and hard capsules (including antitumor drugs)

    新国产三级视频在线播放,三级三级久久三级久久,香港三级纶理在线视,新国产三级视频在线播放